Drugs / TTRNA-DC vaccines
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06514898 | May 2025 → Sep 2027 expected | medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT03334305 | Aug 2018 → Mar 2025 | high grade astrocytic tumor | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT03396575 | Jul 2018 → Mar 2025 | diffuse intrinsic pontine glioma | University of Florida | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTRNA-DC vaccines | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03396575 ↗ |
| Modality | Vaccine | “DC vaccines” NCT03334305 ↗ |
| Route | Other | “given intradermal” NCT06514898 ↗ |